Comparative analysis with collagen type II distinguishes cartilage oligomeric matrix protein as a primary TGFβ-responsive gene

Osteoarthritis and Cartilage

Volumn 19, Issue 10, 2011, Pages 1246-1253

  Li, H ^a   Haudenschild, D R ^a   Posey, K L ^b   Hecht, J T ^b   Di Cesare, P E ^a   Yik, J H N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Chondrocyte differentiation; Chondrogenesis; Sox9; TGF

Indexed keywords

CARTILAGE OLIGOMERIC MATRIX PROTEIN; COLLAGEN TYPE 2; COLLAGEN TYPE 2A1; MESSENGER RNA; TRANSCRIPTION FACTOR SOX9; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW CELL; CELL CULTURE; CELL DIFFERENTIATION; CHONDROCYTE DIFFERENTIATION; CHONDROGENESIS; COMPARATIVE STUDY; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

BONE MARROW CELLS; CHONDROGENESIS; COLLAGEN TYPE II; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION REGULATION; GLYCOPROTEINS; HUMANS; MESENCHYMAL STEM CELLS; SIGNAL TRANSDUCTION; SOX9 TRANSCRIPTION FACTOR; SOXD TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION;

EID: 80052964671     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2011.07.011     Document Type: Article

References (35)

1. Oldberg A., Antonsson P., Lindblom K., Heinegard D. COMP (cartilage oligomeric matrix protein) is structurally related to the thrombospondins. J Biol Chem 1992, 267:22346-22350.
2. Hedbom E., Antonsson P., Hjerpe A., Aeschlimann D., Paulsson M., Rosa-Pimentel E., et al. Cartilage matrix proteins. An acidic oligomeric protein (COMP) detected only in cartilage. J Biol Chem 1992, 267:6132-6136.
3. Newton G., Weremowicz S., Morton C.C., Copeland N.G., Gilbert D.J., Jenkins N.A., et al. Characterization of human and mouse cartilage oligomeric matrix protein. Genomics 1994, 24:435-439.
4. Briggs M.D., Hoffman S.M., King L.M., Olsen A.S., Mohrenweiser H., Leroy J.G., et al. Pseudoachondroplasia and multiple epiphyseal dysplasia due to mutations in the cartilage oligomeric matrix protein gene. Nat Genet 1995, 10:330-336.
5. Hecht J.T., Nelson L.D., Crowder E., Wang Y., Elder F.F., Harrison W.R., et al. Mutations in exon 17B of cartilage oligomeric matrix protein (COMP) cause pseudoachondroplasia. Nat Genet 1995, 10:325-329.
6. Blumbach K., Bastiaansen-Jenniskens Y.M., DeGroot J., Paulsson M., van Osch G.J., Zaucke F. Combined role of type IX collagen and cartilage oligomeric matrix protein in cartilage matrix assembly: cartilage oligomeric matrix protein counteracts type IX collagen-induced limitation of cartilage collagen fibril growth in mouse chondrocyte cultures. Arthritis Rheum 2009, 60:3676-3685.
7. Halasz K., Kassner A., Morgelin M., Heinegard D. COMP acts as a catalyst in collagen fibrillogenesis. J Biol Chem 2007, 282:31166-31173.
8. Hauser N., Paulsson M., Heinegard D., Morgelin M. Interaction of cartilage matrix protein with aggrecan. Increased covalent cross-linking with tissue maturation. J Biol Chem 1996, 271:32247-32252.
9. Rosenberg K., Olsson H., Morgelin M., Heinegard D. Cartilage oligomeric matrix protein shows high affinity zinc-dependent interaction with triple helical collagen. J Biol Chem 1998, 273:20397-20403.
10. Svensson L., Aszodi A., Heinegard D., Hunziker E.B., Reinholt F.P., Fassler R., et al. Cartilage oligomeric matrix protein-deficient mice have normal skeletal development. Mol Cell Biol 2002, 22:4366-4371.
11. Blumbach K., Niehoff A., Paulsson M., Zaucke F. Ablation of collagen IX and COMP disrupts epiphyseal cartilage architecture. Matrix Biol 2008, 27:306-318.
12. Posey K.L., Hankenson K., Veerisetty A.C., Bornstein P., Lawler J., Hecht J.T. Skeletal abnormalities in mice lacking extracellular matrix proteins, thrombospondin-1, thrombospondin-3, thrombospondin-5, and type IX collagen. Am J Pathol 2008, 172:1664-1674.
13. Posey K.L., Davies S., Bales E.S., Haynes R., Sandell L.J., Hecht J.T. In vivo human cartilage oligomeric matrix protein (COMP) promoter activity. Matrix Biol 2005, 24:539-549.
14. Barry F., Boynton R.E., Liu B., Murphy J.M. Chondrogenic differentiation of mesenchymal stem cells from bone marrow: differentiation-dependent gene expression of matrix components. Exp Cell Res 2001, 268:189-200.
15. Recklies A.D., Baillargeon L., White C. Regulation of cartilage oligomeric matrix protein synthesis in human synovial cells and articular chondrocytes. Arthritis Rheum 1998, 41:997-1006.
16. Giannoni P., Siegrist M., Hunziker E.B., Wong M. The mechanosensitivity of cartilage oligomeric matrix protein (COMP). Biorheology 2003, 40:101-109.
17. Zaucke F., Dinser R., Maurer P., Paulsson M. Cartilage oligomeric matrix protein (COMP) and collagen IX are sensitive markers for the differentiation state of articular primary chondrocytes. Biochem J 2001, 358:17-24.
18. Grogan S.P., Olee T., Hiraoka K., Lotz M.K. Repression of chondrogenesis through binding of notch signaling proteins HES-1 and HEY-1 to N-box domains in the COL2A1 enhancer site. Arthritis Rheum 2008, 58:2754-2763.
19. Zuk P.A., Zhu M., Mizuno H., Huang J., Futrell J.W., Katz A.J., et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 2001, 7:211-228.
20. Lefebvre V., Huang W., Harley V.R., Goodfellow P.N., de Crombrugghe B. SOX9 is a potent activator of the chondrocyte-specific enhancer of the pro alpha1(II) collagen gene. Mol Cell Biol 1997, 17:2336-2346.
21. Furumatsu T., Tsuda M., Yoshida K., Taniguchi N., Ito T., Hashimoto M., et al. Sox9 and p300 cooperatively regulate chromatin-mediated transcription. J Biol Chem 2005, 280:35203-35208.
22. Dull T., Zufferey R., Kelly M., Mandel R.J., Nguyen M., Trono D., et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998, 72:8463-8471.
23. Liu C.J., Prazak L., Fajardo M., Yu S., Tyagi N., Di Cesare P.E. Leukemia/lymphoma-related factor, a POZ domain-containing transcriptional repressor, interacts with histone deacetylase-1 and inhibits cartilage oligomeric matrix protein gene expression and chondrogenesis. J Biol Chem 2004, 279:47081-47091.
24. Inman G.J., Nicolas F.J., Callahan J.F., Harling J.D., Gaster L.M., Reith A.D., et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002, 62:65-74.
25. Jinnin M., Ihn H., Tamaki K. Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression. Mol Pharmacol 2006, 69:597-607.
26. Lefebvre V., Behringer R.R., de Crombrugghe B. L-Sox5, Sox6 and Sox9 control essential steps of the chondrocyte differentiation pathway. Osteoarthritis Cartilage 2001, 9(Suppl A):S69-S75.
27. Lefebvre V., Li P., de Crombrugghe B. A new long form of Sox5 (L-Sox5), Sox6 and Sox9 are coexpressed in chondrogenesis and cooperatively activate the type II collagen gene. EMBO J 1998, 17:5718-5733.
28. Han F., Kipnes J.R., Li Y., Tuan R.S., Hall D.J. The murine COMP (cartilage oligomeric matrix protein) promoter contains a potent transcriptional repressor region. Osteoarthritis Cartilage 2002, 10:638-645.
29. Liu C.J., Zhang Y., Xu K., Parsons D., Alfonso D., Di Cesare P.E. Transcriptional activation of cartilage oligomeric matrix protein by Sox9, Sox5, and Sox6 transcription factors and CBP/p300 coactivators. Front Biosci 2007, 12:3899-3910.
30. Kipnes J., Carlberg A.L., Loredo G.A., Lawler J., Tuan R.S., Hall D.J. Effect of cartilage oligomeric matrix protein on mesenchymal chondrogenesis in vitro. Osteoarthritis Cartilage 2003, 11:442-454.
31. Deere M., Rhoades Hall C., Gunning K.B., LeFebvre V., Ridall A.L., Hecht J.T. Analysis of the promoter region of human cartilage oligomeric matrix protein (COMP). Matrix Biol 2001, 19:783-792.
32. Farina G., Lemaire R., Pancari P., Bayle J., Widom R.L., Lafyatis R. Cartilage oligomeric matrix protein expression in systemic sclerosis reveals heterogeneity of dermal fibroblast responses to transforming growth factor beta. Ann Rheum Dis 2009, 68:435-441.
33. Riessen R., Fenchel M., Chen H., Axel D.I., Karsch K.R., Lawler J. Cartilage oligomeric matrix protein (thrombospondin-5) is expressed by human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2001, 21:47-54.
34. Murphy-Ullrich J.E., Poczatek M. Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev 2000, 11:59-69.
35. Crawford S.E., Stellmach V., Murphy-Ullrich J.E., Ribeiro S.M., Lawler J., Hynes R.O., et al. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 1998, 93:1159-1170.